✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Cognitive Enhancement · Provider Directory

Cognitive Enhancement Peptides

Released: Last reviewed:

Cognitive peptides target memory consolidation, neurogenesis, and anxiolytic effects via neuropeptide receptor systems. The most-prescribed via U.S. telehealth include Semax, Selank, Cerebrolysin, Dihexa, and P21. These are research-only in the U.S. and dispensed via 503A compounding pharmacies with prescriber supervision.

6 peptides covered v4.1 methodology All 50 states + DC
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Peptides in this category

Top telehealth providers for cognitive enhancement

See the full provider directory for profiles, dated prices and scores.

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

Related categories

Key facts, checked November 20, 2026

Cognitive peptides such as Semax, Selank, Cerebrolysin and Dihexa are not FDA-approved drugs. Several appear on FDA’s 503A bulk-substance category lists as nominated substances that were withdrawn, so we found no recognized federal pathway for a 503A pharmacy to compound them from bulk. A draft HHS draft peptide policy (91 FR 68526) published October 30, 2026 would, if finalized as summarized by law firms, allow 503A compounding of six peptides including Semax under limits; HHS’s own appendix could not be read. Each peptide page carries a dated status notice; check it before you pay any clinic.